Clinical Trials in Nashville

Showing 8981-9000 of 20,298 trials

Corticosteroids in Community Acquired Pneumonia

NCT04652414

This is a single-center, blinded, placebo-controlled pilot RCT evaluating corticosteroids for the treatment of Community Acquired Pneumonia (CAP) that will enroll 100 adults hospitalized with community-acquired pneumonia. The primary goal is to assess the feasibility of proposed trial procedures for use in a subsequent phase III trial powered on 6-month cognitive outcome (MOCA-Blind score). Key outcomes are six-month cognitive and functional status, duration and severity of symptoms, and mortality.

Community-acquired PneumoniaCognition Disorder

Vanderbilt University Medical CenterStarted Dec 2020

Nashville, Tennessee, United States

COMPLETEDPhase 1< 1 mile

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.

Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more

Pfizer596 participantsStarted Apr 2006

Orange, California, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +26 more locations

Corticosteroids in Community Acquired Pneumonia

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Find Trials by Condition in Nashville

Improving Quality by Maintaining Accurate Problems in the EHR

Mindfulness-Based Stress Reduction for Metro Nashville Public School Employees

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

ECG Belt for CRT Response

Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up

SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Sargramostim Use in COVID-19 to Recover Patient Health

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Characterization & Treatment of Chronic Pain After Moderate to Severe TBI

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Validation of a Salivary miRNA Diagnostic Test for ASD

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake

Peripheral Nerve Stimulation Therapy for Atrial Fibrillation

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis